CD4 cell response to interval therapy with natalizumab

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Natalizumab is a treatment for relapsing multiple sclerosis (MS).
• Peripheral CD4 cell counts are known to be affected by natalizumab therapy.
• Understanding these changes can help monitor treatment efficacy and lymphocyte behavior.

Purpose of the Study:

• To investigate the correlation between CD4 cell counts and different phases of natalizumab treatment in MS patients.
• To assess if CD4 cell counts provide insights into lymphocyte trafficking during treatment and planned interruptions.
• To evaluate the safety and impact of a 12-week natalizumab treatment interruption.

Main Methods:

• Clinical outcomes, MRI data, and CD4 cell counts were measured at baseline, during regular dosing, after a 12-week interruption, and upon reinitiation of natalizumab.
• Patient data were collected across distinct phases of the natalizumab treatment cycle.

Main Results:

• Natalizumab treatment significantly increased peripheral CD4 cell counts compared to baseline.
• CD4 counts returned to baseline levels during the 12-week treatment interruption.
• Reinitiation of natalizumab led to a similar increase in CD4 counts.
• The 12-week interruption was well-tolerated and did not result in MS activity, disability progression, or new MRI findings.

Conclusions:

• Peripheral CD4 cell counts serve as a pharmacodynamic marker for natalizumab treatment in MS.
• Monitoring CD4 cell count fluctuations can aid in understanding lymphocyte trafficking and cell redistribution.
• A 12-week interruption of natalizumab is safe and does not trigger disease reactivation.